File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.radonc.2021.06.020
- Scopus: eid_2-s2.0-85109425926
- PMID: 34139210
- WOS: WOS:000704336600004
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC
Title | Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC |
---|---|
Authors | |
Keywords | Limited-stage SCLC EDIC Lymphocyte nadir Survival |
Issue Date | 2021 |
Publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/radonc |
Citation | Radiotherapy & Oncology, 2021, v. 162, p. 26-33 How to Cite? |
Abstract | Background:
Effective dose to immune cell (EDIC), an estimated radiation dose to the circulating lymphocytes, is of significance for overall survival (OS) in non-small cell lung cancer. This study aimed to validate the EDIC’s OS effect on limited-stage small cell lung cancer (LS-SCLC).
Method and materials:
This study included LS-SCLC patients received definitive chemo-radiation in one single center from 2012 to 2017. All patients had multiple complete-blood-count tests including lymphocyte count at pre-, during- and end- radiotherapy. EDIC, computed according to doses of the lung, heart, and the total body, was assessed for its correlation with lymphocyte nadir, OS and progression free survival (PFS).
Results:
Of 503 eligible patients, the mean EDIC was 7.34 Gy. The mean lymphocyte nadir was 0.48 × 109 cells/L, significantly lower than 1.65 × 109 cells/L at pre-radiotherapy (p < 0.001). EDIC was significantly correlated with lymphocyte nadir under both univariate (p < 0.001) and multivariable linear regression (p < 0.001). Multivariable analysis showed EDIC (HR = 0.1072, p = 0.005) and lymphocyte nadir (HR = 0.345, p = 0.003) were both significant for OS. EDIC was also significant for PFS (HR = 1.046, p = 0.026). The C-indexes of OS prediction were 0.593, 0.617, 0.676, and 0.684, for lymphocyte nadir alone, EDIC alone, combined lymphocyte nadir model, and combined EDIC model, respectively.
Conclusions:
This study demonstrated that EDIC is an independent predictor for lymphocyte nadir, PFS and OS. EDIC may serve as a predictor for lymphocyte nadir and a surrogate marker for OS in LS-SCLC. More attention should be paid to EDIC to decease the lymphocyte toxicity and improve survival. |
Persistent Identifier | http://hdl.handle.net/10722/301942 |
ISSN | 2023 Impact Factor: 4.9 2023 SCImago Journal Rankings: 1.702 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yu, Y | - |
dc.contributor.author | Fu, P | - |
dc.contributor.author | Jin, JY | - |
dc.contributor.author | Gao, S | - |
dc.contributor.author | Wang, W | - |
dc.contributor.author | Machtay, M | - |
dc.contributor.author | Wang, L | - |
dc.contributor.author | Kong, FP | - |
dc.contributor.author | Yu, J | - |
dc.date.accessioned | 2021-08-21T03:29:15Z | - |
dc.date.available | 2021-08-21T03:29:15Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Radiotherapy & Oncology, 2021, v. 162, p. 26-33 | - |
dc.identifier.issn | 0167-8140 | - |
dc.identifier.uri | http://hdl.handle.net/10722/301942 | - |
dc.description.abstract | Background: Effective dose to immune cell (EDIC), an estimated radiation dose to the circulating lymphocytes, is of significance for overall survival (OS) in non-small cell lung cancer. This study aimed to validate the EDIC’s OS effect on limited-stage small cell lung cancer (LS-SCLC). Method and materials: This study included LS-SCLC patients received definitive chemo-radiation in one single center from 2012 to 2017. All patients had multiple complete-blood-count tests including lymphocyte count at pre-, during- and end- radiotherapy. EDIC, computed according to doses of the lung, heart, and the total body, was assessed for its correlation with lymphocyte nadir, OS and progression free survival (PFS). Results: Of 503 eligible patients, the mean EDIC was 7.34 Gy. The mean lymphocyte nadir was 0.48 × 109 cells/L, significantly lower than 1.65 × 109 cells/L at pre-radiotherapy (p < 0.001). EDIC was significantly correlated with lymphocyte nadir under both univariate (p < 0.001) and multivariable linear regression (p < 0.001). Multivariable analysis showed EDIC (HR = 0.1072, p = 0.005) and lymphocyte nadir (HR = 0.345, p = 0.003) were both significant for OS. EDIC was also significant for PFS (HR = 1.046, p = 0.026). The C-indexes of OS prediction were 0.593, 0.617, 0.676, and 0.684, for lymphocyte nadir alone, EDIC alone, combined lymphocyte nadir model, and combined EDIC model, respectively. Conclusions: This study demonstrated that EDIC is an independent predictor for lymphocyte nadir, PFS and OS. EDIC may serve as a predictor for lymphocyte nadir and a surrogate marker for OS in LS-SCLC. More attention should be paid to EDIC to decease the lymphocyte toxicity and improve survival. | - |
dc.language | eng | - |
dc.publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/radonc | - |
dc.relation.ispartof | Radiotherapy & Oncology | - |
dc.subject | Limited-stage SCLC | - |
dc.subject | EDIC | - |
dc.subject | Lymphocyte nadir | - |
dc.subject | Survival | - |
dc.title | Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC | - |
dc.type | Article | - |
dc.identifier.email | Kong, FP: kong0001@hku.hk | - |
dc.identifier.authority | Kong, FP=rp02508 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.radonc.2021.06.020 | - |
dc.identifier.pmid | 34139210 | - |
dc.identifier.scopus | eid_2-s2.0-85109425926 | - |
dc.identifier.hkuros | 324241 | - |
dc.identifier.volume | 162 | - |
dc.identifier.spage | 26 | - |
dc.identifier.epage | 33 | - |
dc.identifier.isi | WOS:000704336600004 | - |
dc.publisher.place | Ireland | - |